Study details
Enrolling now
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
Bantam Pharmaceuticals
NCT IDNCT06792734ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
24
Study length
about 2.9 years
Ages
18+
Locations
1 site in TX
What this study is about
Researchers are testing a new treatment, BTM-3566, to see if it can be safely given to adults with relapsed or refractory mature b cell lymphomas. The trial will also determine how well this treatment works and what side effects occur at different doses.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take BTM-3566
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Adverse Event and dose-limiting toxicity event rates